CytomX Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 2.34 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 509.88M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company’s development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Details
| Name | CytomX Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 69 |
| Founded | 2008 |
| Ipo Date | 2015-10-08 |
| Ceo | Sean McCarthy |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US23284F1057 |
| Cusip | 23284F105 |
| Cik | 0001501989 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Sean A. McCarthy DPHIL | Chairman and Chief Executive Officer |
| Christopher W. Ogden | SVice President, Chief Financial Officer and Secretary |
| Rachael Lester | Chief Business Officer and Senior Vice President |
| Dr. Marcia P. Belvin Ph.D. | Senior Vice President and Chief Scientific Officer |
| Alejandra Veronica Carvajal J.D. | Chief Legal Officer |
| Danielle Olander-Moghadassian | Senior Vice President and Chief Human Resources Officer |
| Leslie Robbins J.D. | Senior Vice President of Intellectual Property |
| Dr. Yu-Waye Chu M.D. | Senior Vice President and Chief Medical Officer |
| Dawn Benson | Senior Vice President of Quality and Product Manufacturing |
| Dr. Stephanie Robertson Ph.D. | Senior Vice President of Alliances and Program Leadership |
Contact
| Address | 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080, United States |
| Phone | 650 515 3185 |
| Website | https://www.cytomx.com |